AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33818780 — intervention group
Group type: EXPERIMENTAL
Intervention: ubrogepant 100 mg after galcanezumab 240 mg
Number of subjects: 40
Study 33818780 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs) with ubrogepant coadministered with erenumab or galcanezumab
Number of subjects: 40
Study 35916348 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg
Number of subjects: 3488
Study 35916348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3488
Study 32366927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (SIL, 50 mg twice daily)
Number of subjects: 50
Study 36345026 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa)
Number of subjects: 311
Study 36345026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GnRHa)
Number of subjects: 311
Study 33444458 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized yoga intervention
Number of subjects: 6
Study 33444458 — intervention group
Group type: COMPARATOR
Intervention: iPad control program
Number of subjects: 6
Study 33971211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun safety intervention (exact details not specified)
Number of subjects: 3710
Study 33971211 — intervention group
Group type: COMPARATOR
Intervention: Observation-only control group
Number of subjects: 3710
Study 34391418 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of glucocorticoid treatment
Number of subjects: 178
Study 34391418 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days of glucocorticoid treatment
Number of subjects: 178
Study 32603993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 0
Study 32603993 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline predictors (including pretreatment worry scores, number of comorbid conditions, hypertension, working memory task scores, hippocampal volumes)
Number of subjects: 0
Study 32603993 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory tasks
Number of subjects: 0
Study 35144636 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate therapy (n=2673)
Number of subjects: 5340
Study 35144636 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=2667)
Number of subjects: 5340
Study 35144636 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum LDL-C during follow-up
Number of subjects: 5340
Study 35144636 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit LDL-C variability
Number of subjects: 5340
Study 34537830 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564
Study 34824052 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 78
Study 34824052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 36103174 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted psychotherapy
Number of subjects: 0
Study 36103174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33630160 — intervention group
Group type: EXPERIMENTAL
Intervention: −50% ICM reduction models
Number of subjects: 85
Study 33630160 — intervention group
Group type: EXPERIMENTAL
Intervention: −80% ICM reduction models
Number of subjects: 85
Study 32958718 — intervention group
Group type: EXPERIMENTAL
Intervention: Early favipiravir therapy (starting on day 1)
Number of subjects: 89
Study 32958718 — intervention group
Group type: COMPARATOR
Intervention: Late favipiravir therapy (starting on day 6)
Number of subjects: 89
Study 32958718 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir (both early and late)
Number of subjects: 89
Study 35253571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine before stenting
Number of subjects: 228
Study 35253571 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 228
Study 32993343 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-doped polyethylene (vE-PE) liner
Number of subjects: 127
Study 32993343 — intervention group
Group type: COMPARATOR
Intervention: Standard cross-linked polyethylene (XLPE) liner
Number of subjects: 127
Study 32993343 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mm femoral head
Number of subjects: 127
Study 32993343 — intervention group
Group type: COMPARATOR
Intervention: 36 mm femoral head
Number of subjects: 127
Study 33813328 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib monotherapy
Number of subjects: 62
Study 33813328 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib plus carboplatin-pemetrexed combination therapy
Number of subjects: 62
Study 32426889 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 1660
Study 36029642 — intervention group
Group type: EXPERIMENTAL
Intervention: SB fading manipulation
Number of subjects: 115
Study 36029642 — intervention group
Group type: COMPARATOR
Intervention: No-instruction control
Number of subjects: 115
Study 33367744 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulacimstat 25 mg twice daily
Number of subjects: 147
Study 33367744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 33367744 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulacimstat
Number of subjects: 147
Study 32253520 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for 6 weeks, load adjusted to 40% of maximal inspiratory pressure
Number of subjects: 31
Study 32253520 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group (CG) for 6 weeks, load adjusted to a minimum placebo load (9 cm H2O)
Number of subjects: 31
Study 32253520 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 31
Study 32253520 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group (CG)
Number of subjects: 31
Study 35168906 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainee guided simulation
Number of subjects: 100
Study 35168906 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised group
Number of subjects: 100
Study 33989990 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy based on articulatory techniques
Number of subjects: 50
Study 34763534 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure at five specific acupressure points (1 min/point, twice a day for 4 weeks)
Number of subjects: 15
Study 34763534 — intervention group
Group type: COMPARATOR
Intervention: Non-specific acupressure at five non-specific acupressure points (1 min/point, twice a day for 4 weeks)
Number of subjects: 15
Study 34507586 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan meal (V)
Number of subjects: 40
Study 34507586 — intervention group
Group type: COMPARATOR
Intervention: Conventional meal (M)
Number of subjects: 40
Study 36474344 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 30 days
Number of subjects: 228
Study 36474344 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily for 30 days
Number of subjects: 228
Study 33303457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Ketodex (combination of dexmedetomidine and ketamine)
Number of subjects: 410
Study 33303457 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketamine
Number of subjects: 410
Study 33303457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Ketodex
Number of subjects: 410
Study 36055307 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy
Number of subjects: 0
Study 36055307 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34187524 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic EEG-guided Radiofrequency Thermocoagulation (RF-TC)
Number of subjects: 0
Study 34187524 — intervention group
Group type: COMPARATOR
Intervention: Anterior Temporal Lobectomy (ATL)
Number of subjects: 0
Study 35152961 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual real-time radiology consultation with referring PCPs and patients, including discussion of CT images focused on vascular atherosclerosis.
Number of subjects: 107
Study 35152961 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual real-time radiology consultation with referring PCPs and patients.
Number of subjects: 107
Study 35152961 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in prescriptions for statins or antihypertensive medications after consultation.
Number of subjects: 107
Study 34847717 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound photography for assessment of surgical site infection (SSI)
Number of subjects: 1478
Study 34847717 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound photography for assessment of wound healing
Number of subjects: 1478
Study 35660843 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 217
Study 35660843 — intervention group
Group type: COMPARATOR
Intervention: Liberal oxygen therapy
Number of subjects: 217
Study 32696911 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 60
Study 32696911 — intervention group
Group type: EXPERIMENTAL
Intervention: Endofill
Number of subjects: 60
Study 32696911 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Fillapex
Number of subjects: 60
Study 35956400 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (1.5 g/day)
Number of subjects: 52
Study 35956400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 35351388 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gamma tACS (40 Hz for 20 min)
Number of subjects: 43
Study 35351388 — intervention group
Group type: COMPARATOR
Intervention: Sham gamma tACS
Number of subjects: 43
Study 33028115 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis stimulating agents (ESAs)
Number of subjects: 0
Study 36481768 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimalist shoes
Number of subjects: 51
Study 32684181 — intervention group
Group type: EXPERIMENTAL
Intervention: MEmory Specificity Training (MEST)
Number of subjects: 48
Study 32684181 — intervention group
Group type: COMPARATOR
Intervention: Non-active control group
Number of subjects: 48
Study 32649485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroactive dressing
Number of subjects: 450
Study 32649485 — intervention group
Group type: COMPARATOR
Intervention: Adhesive tape (standard of care)
Number of subjects: 450
Study 34465809 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgenic overexpression of human KAL gene (KS-Tg)
Number of subjects: 0
Study 34465809 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of recombinant human KAL (rhKAL)
Number of subjects: 0
Study 34465809 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of rhKAL to vascular smooth muscle cells
Number of subjects: 0
Study 32626744 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 55
Study 32626744 — intervention group
Group type: COMPARATOR
Intervention: Placebo Inspiratory Muscle Training (P-IMT)
Number of subjects: 55
Study 34604918 — intervention group
Group type: COMPARATOR
Intervention: Alveolar corticotomy (AC)
Number of subjects: 51
Study 34604918 — intervention group
Group type: COMPARATOR
Intervention: Piezocision (PZ)
Number of subjects: 51
Study 34604918 — intervention group
Group type: EXPERIMENTAL
Intervention: GCF bone remodeling samples
Number of subjects: 51
Study 32644883 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress manipulation (Study 1a)
Number of subjects: 120
Study 32644883 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation (Study 1b)
Number of subjects: 120
Study 32644883 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (Study 2)
Number of subjects: 120
Study 34901039 — intervention group
Group type: EXPERIMENTAL
Intervention: RD1 group (15 ml of 0.375% ropivacaine plus 0.5 μg/kg DEX with 0.1 mg/kg dexamethasone)
Number of subjects: 108
Study 34901039 — intervention group
Group type: EXPERIMENTAL
Intervention: RD2 group (15 ml of 0.375% ropivacaine plus 1.0 μg/kg DEX with 0.1 mg/kg dexamethasone)
Number of subjects: 108
Study 34901039 — intervention group
Group type: COMPARATOR
Intervention: R group (15 ml of 0.375% ropivacaine with 0.1 mg/kg dexamethasone)
Number of subjects: 108
Study 33079403 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CHG-impregnated cloths
Number of subjects: 174
Study 33079403 — intervention group
Group type: COMPARATOR
Intervention: Control cloths
Number of subjects: 174
Study 35081161 — intervention group
Group type: EXPERIMENTAL
Intervention: hPBL group (access to PBL modules)
Number of subjects: 53
Study 35081161 — intervention group
Group type: COMPARATOR
Intervention: BL group (without access to PBL modules)
Number of subjects: 53
Study 33767063 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat
Number of subjects: 1342
Study 33767063 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 1342
Study 32588047 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk supplement (2 × 30 g/d) and exercise program (2 × 1 h/wk including resistance, balance, and aerobic training)
Number of subjects: 180
Study 32588047 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 180
Study 35866799 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU daily)
Number of subjects: 73
Study 35866799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 33407133 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-locus SSR markers
Number of subjects: 27
Study 33407133 — intervention group
Group type: COMPARATOR
Intervention: Multi-locus SSR markers
Number of subjects: 27
Study 32665372 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of transmitted recorded home oximetry (RHO) data
Number of subjects: 196
Study 32665372 — intervention group
Group type: COMPARATOR
Intervention: Standard monthly clinic visit assessments
Number of subjects: 196
Study 32665372 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 196
Study 34975829 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg Oral Immunotherapy (OIT)
Number of subjects: 50
Study 33171557 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time navigation guided implant insertion
Number of subjects: 24
Study 33171557 — intervention group
Group type: COMPARATOR
Intervention: Free-hand implant insertion
Number of subjects: 24
Study 33171557 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with length <47.5 mm
Number of subjects: 24
Study 33171557 — intervention group
Group type: COMPARATOR
Intervention: Implants with length ≥47.5 mm
Number of subjects: 24
Study 33171557 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal implant group
Number of subjects: 24
Study 33171557 — intervention group
Group type: COMPARATOR
Intervention: Distal implant group
Number of subjects: 24
Study 36394874 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Optimization (MED group)
Number of subjects: 261
Study 36394874 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT group)
Number of subjects: 261
Study 32865169 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (PO CYC)
Number of subjects: 302
Study 32865169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (IV CYC)
Number of subjects: 302
Study 32865169 — intervention group
Group type: COMPARATOR
Intervention: Both PO and IV CYC
Number of subjects: 302
Study 35378821 — intervention group
Group type: EXPERIMENTAL
Intervention: Shumian Capsule (SMC)
Number of subjects: 26
Study 35378821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 33025252 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 169
Study 33025252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 35658479 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 213
Study 35658479 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus temsirolimus
Number of subjects: 213
Study 34530857 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 0
Study 34530857 — intervention group
Group type: COMPARATOR
Intervention: Western diet (WD)
Number of subjects: 0
Study 35656222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention message targeting kin care motive
Number of subjects: 969
Study 35656222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention message targeting disease avoidance motive
Number of subjects: 969
Study 35656222 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 969
Study 35466341 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care requirements for children who died in the PICU
Number of subjects: 104
Study 35466341 — intervention group
Group type: COMPARATOR
Intervention: Circumstances of death (withdrawal of life-sustaining treatments, failed resuscitation, brain death)
Number of subjects: 104
Study 35466341 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness trajectory (acute, complex chronic condition, or cancer)
Number of subjects: 104
Study 35466341 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of PICU stay
Number of subjects: 104
Study 35466341 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical care devices
Number of subjects: 104
Study 32869589 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at tendon blockage point of quadriceps femoris muscle belly
Number of subjects: 76
Study 32869589 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate injection into articular cavity
Number of subjects: 76
Study 36608979 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Number of subjects: 53
Study 36608979 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Training (ACT)
Number of subjects: 53
Study 36608979 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ABMT and ACT
Number of subjects: 53
Study 33043591 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg BID)
Number of subjects: 46
Study 33043591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 33968372 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic characteristics (age, sex, education, residential location)
Number of subjects: 90551
Study 33968372 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor tooth brushing habit
Number of subjects: 90551
Study 33968372 — intervention group
Group type: EXPERIMENTAL
Intervention: Having teeth
Number of subjects: 90551
Study 35020465 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-CEX (docetaxel plus capecitabine followed by cyclophosphamide, epirubicin, and capecitabine)
Number of subjects: 1500
Study 35020465 — intervention group
Group type: COMPARATOR
Intervention: T-CEF (docetaxel followed by cyclophosphamide, epirubicin, and fluorouracil)
Number of subjects: 1500
Study 33370173 — intervention group
Group type: EXPERIMENTAL
Intervention: Masks (general use in the community)
Number of subjects: 0
Study 33370173 — intervention group
Group type: COMPARATOR
Intervention: Community mask recommendation (from 1 randomized controlled trial)
Number of subjects: 0
Study 36193496 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal repair
Number of subjects: 130
Study 36193496 — intervention group
Group type: COMPARATOR
Intervention: Tension-free hernia repair (control group)
Number of subjects: 130
Study 32462496 — intervention group
Group type: EXPERIMENTAL
Intervention: Real c‐iTBS
Number of subjects: 8
Study 32462496 — intervention group
Group type: COMPARATOR
Intervention: Sham c‐iTBS
Number of subjects: 8
Study 35595673 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Radial Access (DRA)
Number of subjects: 1307
Study 35595673 — intervention group
Group type: COMPARATOR
Intervention: Conventional Transradial Access (TRA)
Number of subjects: 1307
Study 34578917 — intervention group
Group type: EXPERIMENTAL
Intervention: KB290 + βC beverage
Number of subjects: 100
Study 34578917 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 100
Study 36396433 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT with MT
Number of subjects: 396
Study 36396433 — intervention group
Group type: COMPARATOR
Intervention: MT alone
Number of subjects: 396
Study 33478501 — intervention group
Group type: EXPERIMENTAL
Intervention: TAT-modified serum albumin nanoparticles (TAT-TMP-NPs)
Number of subjects: 0
Study 33478501 — intervention group
Group type: COMPARATOR
Intervention: Other treatment groups (not specified)
Number of subjects: 0
Study 32502050 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-guided educational intervention (13-minute captioned video clips with school engagement themes)
Number of subjects: 46
Study 32502050 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual control group
Number of subjects: 46
Study 35478070 — intervention group
Group type: EXPERIMENTAL
Intervention: Aniseikonia-correcting spectacle lenses
Number of subjects: 0
Study 35478070 — intervention group
Group type: COMPARATOR
Intervention: Standard spectacle lenses
Number of subjects: 0
Study 33859214 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsivity-focused group intervention (IG)
Number of subjects: 56
Study 33859214 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 56
Study 36054211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 2298
Study 36054211 — intervention group
Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 2298
Study 36054211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobar CAA ICH
Number of subjects: 2298
Study 36054211 — intervention group
Group type: EXPERIMENTAL
Intervention: Other types of ICH
Number of subjects: 2298
Study 34483189 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention offering pregnancy and childbirth support
Number of subjects: 39
Study 35034530 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D cues to body volume (binocular presentation)
Number of subjects: 412
Study 35034530 — intervention group
Group type: COMPARATOR
Intervention: 2D cues only (monocular presentation)
Number of subjects: 412